Peptide Initiative

Peptide profile · Immune

Bestatin (Ubenimex)

Natural dipeptide analogue aminopeptidase inhibitor with dual immunostimulatory and antitumor activity, approved in Japan as adjuvant cancer therapy

Moderate human trialsResearch compound
Approximately 2-3 hoursHalf-life (oral administration)
Well absorbed orally; peak plasma concentration reached within 1-2 hoursBioavailability
308.37Molecular weight, g/mol

Molecular formula

C16H24N2O4

CAS number
58970-76-6
PubChem
72172
Developed · 1976
Hamao Umezawa, Institute of Microbial Chemistry, Tokyo / Nippon Kayaku Co., Ltd.

Amino acid sequence

(2S,3R)-3-Amino-2-hydroxy-4-phenylbutanoyl-Leucine (dipeptide analogue)

ImmuneBestatin is a well-characterized immunostimulant that activates T-lymphocytes, macrophages, and natural killer cells while enhancing IL-1 and IL-2 production. Approved in Japan as an adjunctive immunotherapy for acute non-lymphocytic leukemia, it has decades of clinical evidence supporting its immune-enhancing properties .

9.0

Healing & RecoveryBy stimulating bone marrow stem cell proliferation and enhancing immune recovery after chemotherapy, bestatin supports the body's regenerative processes during cancer treatment. Clinical trials have demonstrated improved survival times in AML patients who achieve complete remission .

7.0

Anti-AgingBestatin's ability to enhance immune surveillance and modulate inflammatory pathways through LTA4 hydrolase inhibition has potential implications for age-related immune decline and chronic inflammatory conditions, though direct anti-aging research is limited.

4.0

Ratings out of 10.

30mg

Every documented dose level

PhaseDoseFrequency
Long-term, alongside maintenance chemotherapy30 mgOnce daily
Build my protocolBuild my protocol opens your schedule and dose log to save, share and keep on your phone.

Best for adjunctive immunotherapy following chemotherapy for acute leukemia & restoring immune function during and after cancer treatment

Best for

  • Adjunctive AML Immunotherapy

    Bestatin is specifically approved in Japan for patients with acute non-lymphocytic leukemia who have achieved complete remission after induction chemotherapy. Clinical trials demonstrated significant prolongation of disease-free survival when bestatin was added to standard maintenance therapy .

  • Post-Chemotherapy Immune Recovery

    By stimulating bone marrow stem cell proliferation and enhancing T-lymphocyte and macrophage function, bestatin supports immune system recovery in patients whose immune function has been suppressed by cytotoxic chemotherapy .

  • Pulmonary Arterial Hypertension (Investigational)

    Through inhibition of LTA4 hydrolase and reduction of pro-inflammatory leukotriene B4, bestatin is being investigated as a novel approach to PAH. Eiger BioPharmaceuticals conducted Phase 2 trials (NCT02664558) and received FDA orphan drug designation for this indication .

  • Lymphedema Management (Investigational)

    The anti-inflammatory properties of bestatin via LTB4 pathway inhibition have led to Phase 2 investigation (NCT02700529) for lymphedema, a condition with limited treatment options where inflammation plays a key role in disease progression.

Consider alternatives if

Immune enhancement during cancer treatmentThymosin Alpha-1 (thymic peptide immunomodulator, approved in some countries)Levamisole (antihelminthic with immunostimulant properties, formerly used in colon cancer)BCG immunotherapy (for bladder cancer, different mechanism)
Aminopeptidase inhibition for cancer therapyTosedostat (CHR-2797, aminopeptidase inhibitor in clinical development)Actinonin (metalloprotease inhibitor, research compound)Proteasome inhibitors like bortezomib (different protein degradation pathway)
Pulmonary arterial hypertension treatmentBosentan (endothelin receptor antagonist, FDA approved for PAH)Sildenafil (PDE5 inhibitor, approved for PAH)Treprostinil (prostacyclin analogue, multiple formulations)

Do not use if

  • You have a known allergy or hypersensitivity to bestatin or related aminopeptidase inhibitors
  • You are pregnant or breastfeeding — safety in pregnancy has not been established
  • You have severe, uncompensated liver disease — bestatin may worsen hepatic function
  • You have an active autoimmune disease in flare where immune stimulation could be harmful

Use with caution if

  • You are taking immunosuppressive medications — bestatin's immunostimulatory effects may counteract immunosuppression
  • You are taking ACE inhibitors — bestatin may potentiate hypotensive effects through overlapping aminopeptidase pathways
  • You have moderate hepatic impairment — monitor liver function closely during treatment
  • You have a history of severe drug allergies or atopic conditions

Not sure?

Compare Bestatin (Ubenimex) with similar peptides to find the best fit for your goals.

Route

Bestatin (Ubenimex) is administered Oral (capsule)—no injection required

Best sites

  • Not applicable—this is not an injectable formulation

The Bestatin (Ubenimex) dosing protocol covers how it is taken.

4 common side effects · 2 serious

Emergency signs first, then what this page and MedlinePlus say.

Bestatin (ubenimex) has an established safety profile based on decades of clinical use in Japan for AML maintenance therapy at 30 mg daily.

The compound is generally well-tolerated, with the most common side effects being mild gastrointestinal symptoms and skin reactions. Japanese post-marketing surveillance and long-term clinical studies have not identified major safety concerns at standard doses.

Phase 2 trials in the US for PAH and lymphedema also demonstrated acceptable safety profiles at higher doses.

Safety data is supported by Japanese regulatory approval, Phase 1-2 clinical trials, and decades of post-marketing surveillance. FDA orphan drug designation for PAH indicates adequate safety data for continued clinical development.

Most safety data comes from Japanese clinical experience; data in non-Japanese populations is more limited.


Common side effects · experienced by some users

Gastrointestinal discomfort

Mild nausea, diarrhea, or abdominal discomfort are the most frequently reported side effects with oral bestatin. These are typically transient and occur during the first week of treatment .

Management
Take with a small amount of food or water if stomach upset occurs. Symptoms usually resolve within a few days of continued use. If persistent, consider temporary dose reduction.

Skin rash or pruritus

Mild skin reactions including rash, itching, or urticaria have been reported in a subset of patients. These are generally mild and do not require discontinuation .

Management
Antihistamines may provide symptomatic relief. If rash is widespread or accompanied by systemic symptoms, discontinue and consult healthcare provider. Usually resolves within days of stopping treatment.

Facial flushing

Transient facial flushing or warmth may occur, particularly during the initial days of treatment, likely related to immune activation and histamine release.

Management
Usually self-limiting and resolves within 30-60 minutes of dosing. No treatment required. If persistent or bothersome, dose reduction may help.

Fatigue

Mild fatigue or malaise may occur as the immune system is stimulated. This is more commonly noted in patients concurrently receiving chemotherapy.

Management
Ensure adequate rest and hydration. Fatigue typically improves after the first 1-2 weeks of treatment. May be managed with dose timing adjustment to evening if daytime fatigue is problematic.

Serious side effects

Severe allergic reaction

In rare cases, severe hypersensitivity reactions including angioedema or anaphylaxis-like symptoms may occur. This is extremely uncommon given bestatin's small molecular size.

Management
Discontinue immediately and seek emergency medical attention. Patients with a history of severe drug allergies should be monitored closely during initial dosing. Have emergency medications available for first doses.

Less commonElevated liver enzymesMild leukopenia

These typically resolve with continued use or dose adjustment.


Stop and seek help if

  • Severe allergic reaction (rash, swelling, difficulty breathing)
  • Significant liver enzyme elevation (AST/ALT >3x upper limit of normal)
  • Persistent or worsening side effects despite dose adjustment
  • Disease relapse requiring change in treatment protocol
  • Physician determines treatment goals have been achieved or treatment is no longer beneficial

Always consult with your healthcare provider before stopping bestatin, especially during cancer treatment. Abrupt discontinuation during AML maintenance therapy should only be done under medical supervision.


With other peptides

  • SafeThymosin Alpha-1 — Both enhance immune function through complementary mechanisms — Thymosin Alpha-1 promotes thymic T-cell maturation while bestatin enhances peripheral T-cell activation. Combination may provide synergistic immune support but should be monitored for excessive immune stimulation.
  • SafeThymopentin (TP-5) — Complementary immune enhancement pathways. TP-5 modulates thymic function while bestatin acts on aminopeptidases. No known negative interactions, but combination has not been extensively studied.
  • SafeBPC-157 focuses on tissue repair while bestatin targets immune function. No overlapping mechanisms or known interactions. Can likely be used concurrently without issues.

With medications

  • SafeChemotherapy agents (cytarabine, daunorubicin) — Bestatin is specifically designed and approved to be used alongside AML chemotherapy. Clinical trials demonstrated synergistic benefits with standard induction and maintenance regimens.
  • CautionImmunosuppressants (cyclosporine, tacrolimus) — Bestatin's immunostimulatory effects directly counteract immunosuppressive therapy. Avoid concurrent use or use only with careful immune monitoring.
  • CautionACE inhibitors — Bestatin inhibits aminopeptidases involved in angiotensin metabolism, which may potentiate the hypotensive effects of ACE inhibitors. Monitor blood pressure closely if used together.
  • SafeAntibiotics — No known negative interactions with common antibiotics. Bestatin may complement antibiotic therapy by enhancing immune clearance of infections.

With supplements

  • SafeVitamin D supports immune function through complementary pathways and may enhance bestatin's immunostimulatory effects. Safe to combine.
  • SafeZinc is essential for proper immune cell function and T-lymphocyte development. May complement bestatin's immune-enhancing effects. Safe to combine.
  • SafeGreen tea extract (EGCG) — EGCG has aminopeptidase inhibitory properties that may overlap with bestatin. While generally safe, combining multiple aminopeptidase inhibitors may lead to additive effects. Use with awareness.

Moderate human trials · first signs week 1-2

Evidence level

Moderate human trials

(Phase 1-2)

80/100

Regulatory status

Research compound

Onset of effects

Moderate

(1-2 weeks)


How it works

Bestatin is a small molecule immunomodulator that enhances immune function by preventing the breakdown of important immune-signaling peptides.

It works by inhibiting aminopeptidases, enzymes that degrade peptide hormones used by immune cells for communication. This extends the activity of these immune signals, boosting T cell function and natural killer cell activity against infections and cancer .

The deeper mechanism

Bestatin (ubenimex) is a competitive inhibitor targeting three key enzymes: aminopeptidase B (APB), leucine aminopeptidase (LAP), and leukotriene A4 hydrolase (LTA4H).

The immunostimulatory mechanism operates through several converging pathways: (1) Inhibition of cell-surface aminopeptidases on antigen-presenting cells enhances MHC class I-restricted antigen processing and presentation, leading to increased CD8+ cytotoxic T-lymphocyte activation; (2) Enhanced production of interleukin-1 (IL-1) from activated macrophages drives T-helper cell proliferation and IL-2 secretion, amplifying adaptive immune responses; (3) Direct macrophage activation increases phagocytic activity, reactive oxygen species production, and tumoricidal capacity; (4) Stimulation of bone marrow colony-forming units (CFU-GM, BFU-E) promotes hematopoietic recovery following myelosuppressive therapy.

The anti-inflammatory mechanism centers on LTA4H inhibition, which prevents the conversion of leukotriene A4 to leukotriene B4 (LTB4), a potent neutrophil chemoattractant and pro-inflammatory mediator.

In pulmonary arterial hypertension, LTB4 drives macrophage accumulation, smooth muscle cell proliferation, and vascular remodeling in pulmonary arterioles. By reducing LTB4 levels, bestatin may attenuate these pathological processes.

The compound's structural basis — a phenylalanine-leucine dipeptide analogue with a unique (2S,3R)-3-amino-2-hydroxy moiety — provides specific competitive binding to the zinc-containing active sites of target aminopeptidases.


What to expect

  1. Week 1-2

    What you might notice

    • Immune system priming begins as aminopeptidase inhibition takes effect
    • Enhanced IL-1 and IL-2 production begins within days of starting treatment
    • Mild increase in energy levels as immune function begins to improve

    What's normal

    • Mild GI discomfort or facial flushing during the first few days
    • No dramatic outward changes — immune modulation works at the cellular level initially
    • Blood work may not yet show measurable changes in immune parameters

    What's next

    • Continue consistent daily dosing at the prescribed amount
    • Immune activation cascades are building but take time to become clinically apparent
    • First blood tests may be scheduled to monitor baseline immune cell counts
  2. Week 2-6

    What you might notice

    • Measurable increases in T-lymphocyte counts and activity on blood work
    • Enhanced macrophage function and improved innate immune markers
    • In cancer patients: improved tolerance of ongoing treatment protocols
    • General improvement in well-being and reduced susceptibility to infections

    What's normal

    • Gradual improvement in immune markers rather than sudden changes
    • Some fluctuation in blood counts is normal during immune reconstitution
    • In AML patients: maintaining stable complete remission is the primary goal

    What's next

    • Continue treatment as prescribed — benefits accumulate with sustained use
    • Regular blood monitoring to track immune recovery and liver function
    • For AML patients: combination with standard maintenance chemotherapy continues
  3. Week 6-24+

    What you might notice

    • Sustained immune enhancement with stable T-cell and NK cell populations
    • In AML patients: prolonged disease-free survival during maintenance phase
    • Reduced frequency of opportunistic infections during cancer treatment
    • For PAH patients (investigational): potential improvement in exercise capacity and hemodynamics

    What's normal

    • Immune benefits plateau at a maintained enhanced level
    • Long-term treatment is well-tolerated in clinical studies with minimal cumulative toxicity
    • Periodic blood monitoring remains important for long-term therapy

    What's next

    • Continue long-term maintenance as directed by oncologist or prescribing physician
    • Treatment duration in AML is typically 1-2 years or as part of ongoing maintenance protocol
    • Discuss with physician whether dose adjustment is needed based on immune monitoring

Signs it's working

Immune markers

  • Increased T-lymphocyte counts (CD3+, CD4+) on blood work
  • Improved CD4/CD8 ratio indicating balanced immune function
  • Enhanced natural killer cell activity on functional assays
  • Stable or improving white blood cell counts during chemotherapy

Signs it's working

Clinical outcomes

  • Maintained complete remission in AML patients
  • Reduced frequency of infections during cancer treatment
  • Improved energy levels and general well-being
  • No signs of disease relapse on regular monitoring

Not seeing results?

Common reasons

  • Not taking consistently — bestatin requires daily dosing to maintain aminopeptidase inhibition
  • Dose too low — if using 10-20 mg and not seeing immune benefits, discuss escalation to 30 mg with your physician
  • Concurrent immunosuppressive therapy counteracting bestatin's immune-enhancing effects
  • Advanced disease stage where immune enhancement alone is insufficient without adequate chemotherapy
  • Individual variation in aminopeptidase expression levels may affect response

What is the difference between bestatin and ubenimex?

Bestatin and ubenimex are two names for the same compound. 'Bestatin' is the original laboratory name given by its discoverer Hamao Umezawa in 1976, while 'Ubenimex' is the International Nonproprietary Name (INN) used for the approved pharmaceutical product. In Japan, it is marketed under the brand name Bestatin by Nippon Kayaku Co., Ltd. Both names refer to the same dipeptide analogue aminopeptidase inhibitor.

Is bestatin approved by the FDA?

No, bestatin (ubenimex) is not currently approved by the FDA. It has been approved and used in Japan since the 1980s as adjunctive immunotherapy for acute non-lymphocytic leukemia. In the United States, it has received FDA orphan drug designation for pulmonary arterial hypertension, and Phase 2 clinical trials have been conducted for both PAH and lymphedema by Eiger BioPharmaceuticals. While not FDA-approved, it has extensive clinical safety and efficacy data from decades of Japanese clinical use.

How does bestatin differ from other immune supplements?

Bestatin is a pharmaceutical-grade aminopeptidase inhibitor with a highly specific mechanism of action — it competitively inhibits aminopeptidase B, leucine aminopeptidase, and LTA4 hydrolase. Unlike general immune supplements that broadly stimulate immune activity, bestatin works through precise enzyme inhibition that enhances antigen processing, T-lymphocyte activation, and macrophage function while simultaneously reducing pro-inflammatory leukotriene production. It has been validated in randomized clinical trials and has regulatory approval in Japan, setting it apart from over-the-counter immune products.

Can bestatin be used for conditions other than leukemia?

Yes, while bestatin was originally developed and approved for leukemia, its unique mechanism of action has opened new therapeutic avenues. Eiger BioPharmaceuticals conducted Phase 2 trials for pulmonary arterial hypertension (NCT02664558) and lymphedema (NCT02700529), leveraging bestatin's LTA4 hydrolase inhibition to reduce inflammatory vascular remodeling. Research has also explored its potential in solid tumors, autoimmune conditions, and as a broad immunostimulant for immunocompromised patients.

What is the recommended dose of bestatin?

The standard therapeutic dose used in Japanese clinical practice is 30 mg once daily, taken orally. Phase 1 clinical trials established an optimal dose range of 10-100 mg daily. For leukemia maintenance, 30 mg daily is standard. For investigational indications like PAH, higher doses may be used under physician supervision. Treatment duration varies by indication — in AML maintenance, courses typically extend for 1-2 years or longer.

How was bestatin discovered?

Bestatin was discovered in 1976 by Professor Hamao Umezawa and his team at the Institute of Microbial Chemistry in Tokyo, Japan. They isolated it from the culture filtrate of Streptomyces olivoreticuli, a soil bacterium. Umezawa was a pioneering researcher in enzyme inhibitors from microbial sources and also discovered other important compounds. Bestatin was identified through screening for small-molecule inhibitors of aminopeptidases, and its immunostimulatory and antitumor properties were subsequently characterized.

Are there serious side effects with bestatin?

Bestatin is generally well-tolerated, with most side effects being mild and transient. Common effects include mild GI discomfort, skin rash, and facial flushing. Uncommon effects include transient liver enzyme elevations and mild decreases in white blood cell counts. Serious side effects such as severe allergic reactions are rare. Long-term Japanese clinical experience over decades has confirmed a favorable safety profile at the standard 30 mg daily dose. Liver function monitoring is recommended during treatment.

Ready for the protocol?

Every dosing tier, administration route, timing note, and dose-adjustment rule for Bestatin (Ubenimex), on one page.

Bestatin (Ubenimex) dosing protocol

Medical disclaimer

Bestatin (Ubenimex) is an investigational research compound not approved by the FDA for human therapeutic use. This information is for educational purposes only and should not be construed as medical advice. Always consult with a qualified healthcare provider before starting any new supplement or treatment protocol.

Last updated: Oct 9, 2026